Skip to content
2000
image of The Thorny Question of Early Diagnosis in Lung Cancer: Should the IP-10 Cytokine be Brought to Trial?

Abstract

Background

Lung cancer remains the leading cause of cancer mortality worldwide, underscoring the need for non-invasive early diagnostic tools. IP-10, a cytokine involved in inflammation and angiogenesis, is a promising candidate. The present study aims to assess the relevance of IP-10 in lung cancer early diagnosis.

Methods

In this cross-sectional study, we measured serum IP-10 levels using Luminex assays in 52 treatment-naïve lung cancer patients without comorbidities and 14 healthy controls. Based on the non-normal distribution of data, group comparisons were performed using Wilcoxon rank-sum tests. Multivariate linear regression was used to adjust for cofounders.

Results

IP-10 levels were significantly elevated in lung cancer patients compared to healthy controls (median: 189.69 pg/mL vs. 108.78 pg/mL, = 0.001). This significance persisted in the early-stage subgroup (stages 0-IIA; median: 192.49 pg/mL . 108.78 pg/mL, = 0.001), even after multivariate adjustment ( = 0.018). Levels peaked in evolved early-stage disease (median: 241.42 pg/mL) before declining in advanced stages, while remaining elevated above controls.

Discussion

The rise in IP-10 levels in early-stage lung cancer patients emphasizes its potential to serve as an early diagnostic biomarker. Meanwhile, the peak-and-decline pattern during phases of disease is consistent with its postulated dual role in early antitumor immunity and later tumor promotion.

Conclusion

IP-10 can potentially be used as a supplemental serum biomarker for early lung cancer diagnosis. This finding calls for additional validation in bigger, multi-center cohorts to define diagnostic thresholds and investigate their incorporation into multi-marker panels.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096415381251122002921
2026-01-12
2026-01-31

  • From This Site

    /content/journals/ccdt/10.2174/0115680096415381251122002921
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bray F. Laversanne M. Sung H. Ferlay J. Siegel R.L. Soerjomataram I. Bray F. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024 74 3 229 263 10.3322/caac.21834
    [Google Scholar]
  2. Passaro A. Al Bakir M. Hamilton E.G. Diehn M. André F. Roy-Chowdhuri S. Mountzios G. Wistuba I.I. Swanton C. Peters S. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell 2024 187 7 1617 1635 10.1016/j.cell.2024.02.041 38552610
    [Google Scholar]
  3. Stephens E.K.H. Guayco Sigcha J. Lopez-Loo K. Yang I.A. Marshall H.M. Fong K.M. Biomarkers of lung cancer for screening and in never-smokers - A narrative review. Transl. Lung Cancer Res. 2023 12 10 2129 2145 10.21037/tlcr‑23‑291 38025810
    [Google Scholar]
  4. Ning J. Ge T. Jiang M. Jia K. Wang L. Li W. Chen B. Liu Y. Wang H. Zhao S. He Y. Early diagnosis of lung cancer: Which is the optimal choice? Aging 2021 13 4 6214 6227 10.18632/aging.202504 33591942
    [Google Scholar]
  5. Zhou Y. Tao L. Qiu J. Xu J. Yang X. Zhang Y. Tian X. Guan X. Cen X. Zhao Y. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct. Target. Ther. 2024 9 1 132 10.1038/s41392‑024‑01823‑2
    [Google Scholar]
  6. Madhurantakam S. Lee Z.J. Naqvi A. Prasad S. Importance of IP-10 as a biomarker of host immune response: Critical perspective as a target for biosensing. Curr. Res. Biotechnol. 2023 5 100130 10.1016/j.crbiot.2023.100130
    [Google Scholar]
  7. Matilla J.M. Zabaleta M. Martínez-Téllez E. Abal J. Rodríguez-Fuster A. Hernández-Hernández J. New TNM staging in lung cancer (8th edition) and future perspectives. J. Clin. Transl. Res. 2020 6 4 145 154 33521375
    [Google Scholar]
  8. Neville L.F. Mathiak G. Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): A novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev. 1997 8 3 207 219 10.1016/S1359‑6101(97)00015‑4 9462486
    [Google Scholar]
  9. Luster A.D. Ravetch J.V. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J. Exp. Med. 1987 166 4 1084 1097 10.1084/jem.166.4.1084 2443596
    [Google Scholar]
  10. Liu M. Guo S. Hibbert J.M. Jain V. Singh N. Wilson N.O. Stiles J.K. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011 22 3 121 130 10.1016/j.cytogfr.2011.06.001 21802343
    [Google Scholar]
  11. Wu L. Xie S. Wang L. Li J. Han L. Qin B. Zhang G. Wu Q. Gao W. Zhang L. Wei H. Liu T. Jiao S. The ratio of IP10 to IL-8 in plasma reflects and predicts the response of patients with lung cancer to anti-PD-1 immunotherapy combined with chemotherapy. Front. Immunol. 2021 12 665147 10.3389/fimmu.2021.665147 33912192
    [Google Scholar]
  12. Clark A.M. Heusey H.L. Griffith L.G. Lauffenburger D.A. Wells A. IP-10 (CXCL10) can trigger emergence of dormant breast cancer cells in a metastatic liver microenvironment. Front. Oncol. 2021 11 676135 10.3389/fonc.2021.676135 34123844
    [Google Scholar]
  13. Greten F.R. Grivennikov S.I. Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity 2019 51 1 27 41 10.1016/j.immuni.2019.06.025 31315034
    [Google Scholar]
  14. Balkwill F. Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001 357 9255 539 545 10.1016/S0140‑6736(00)04046‑0 11229684
    [Google Scholar]
  15. Pawar J.S. Salam M.A. Dipto M.S.U. Al-Amin M.Y. Salam M.T. Sengupta S. Kumari S. Gujjari L. Yadagiri G. Cancer-associated fibroblasts: Immunosuppressive crosstalk with tumor-infiltrating immune cells and implications for therapeutic resistance. Cancers 2025 17 15 2484 10.3390/cancers17152484 40805183
    [Google Scholar]
  16. Li C. Yu X. Han X. Lian C. Wang Z. Shao S. Shao F. Wang H. Ma S. Liu J. Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy. iScience 2024 27 9 110750 10.1016/j.isci.2024.110750 39280627
    [Google Scholar]
  17. Radandish M. Mashhadi N. Aghayan A.H. Taghizadeh M. Salehianfard S. Yahyazadeh S. Vakili O. Igder S. In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy. Exp. Hematol. Oncol. 2025 14 1 105 10.1186/s40164‑025‑00695‑8 40784879
    [Google Scholar]
  18. House I.G. Savas P. Lai J. Chen A.X.Y. Oliver A.J. Teo Z.L. Todd K.L. Henderson M.A. Giuffrida L. Petley E.V. Sek K. Mardiana S. Gide T.N. Quek C. Scolyer R.A. Long G.V. Wilmott J.S. Loi S. Darcy P.K. Beavis P.A. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin. Cancer Res. 2020 26 2 487 504 10.1158/1078‑0432.CCR‑19‑1868 31636098
    [Google Scholar]
  19. Jarczak D. Nierhaus A. Cytokine storm-definition, causes, and implications. Int. J. Mol. Sci. 2022 23 19 11740 10.3390/ijms231911740 36233040
    [Google Scholar]
  20. Bufi A.A. Di Stefano J. Papait A. Silini A.R. Parolini O. Ponsaerts P. The central role of CXCL10-CXCR3 signaling in neuroinflammation and neuropathology. Cytokine Growth Factor Rev. 2025 84 20 34 10.1016/j.cytogfr.2025.05.003 40473519
    [Google Scholar]
  21. Dufour J.H. Dziejman M. Liu M.T. Leung J.H. Lane T.E. Luster A.D. IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 2002 168 7 3195 3204 10.4049/jimmunol.168.7.3195 11907072
    [Google Scholar]
  22. Arenberg D.A. Kunkel S.L. Polverini P.J. Morris S.B. Burdick M.D. Glass M.C. Taub D.T. Iannettoni M.D. Whyte R.I. Strieter R.M. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 1996 184 3 981 992 10.1084/jem.184.3.981 9064358
    [Google Scholar]
  23. Loetscher M. Gerber B. Loetscher P. Jones S.A. Piali L. Clark-Lewis I. Baggiolini M. Moser B. Chemokine receptor specific for IP10 and mig: Structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 1996 184 3 963 969 10.1084/jem.184.3.963 9064356
    [Google Scholar]
  24. Qin S. Rottman J.B. Myers P. Kassam N. Weinblatt M. Loetscher M. Koch A.E. Moser B. Mackay C.R. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 1998 101 4 746 754 10.1172/JCI1422 9466968
    [Google Scholar]
  25. Lunardi S. Lim S.Y. Muschel R.J. Brunner T.B. IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer. OncoImmunology 2015 4 9 e1027473 10.1080/2162402X.2015.1027473 26405599
    [Google Scholar]
  26. Bronger H. Singer J. Windmüller C. Reuning U. Zech D. Delbridge C. Dorn J. Kiechle M. Schmalfeldt B. Schmitt M. Avril S. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br. J. Cancer 2016 115 5 553 563 10.1038/bjc.2016.172 27490802
    [Google Scholar]
  27. Chang C. Wang M.J. Bi X.F. Fan Z.Y. Feng D. Cai H.Q. Zhang Y. Xu X. Cai Y. Qi J. Wei W.Q. Hao J.J. Wang M.R. Elevated serum eotaxin and IP‐10 levels as potential biomarkers for the detection of esophageal squamous cell carcinoma. J. Clin. Lab. Anal. 2021 35 9 e23904 10.1002/jcla.23904 34288108
    [Google Scholar]
  28. Liu M. Guo S. Stiles J.K. The emerging role of CXCL10 in cancer. Oncol. Lett. 2011 2 4 583 589 10.3892/ol.2011.300 22848232
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096415381251122002921
Loading
The Thorny Question of Early Diagnosis in Lung Cancer: Should the IP-10 Cytokine be Brought to Trial?
Bentham Science Publishers ; https://doi.org/10.2174/0115680096415381251122002921
/content/journals/ccdt/10.2174/0115680096415381251122002921
/content/journals/ccdt/10.2174/0115680096415381251122002921
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: angiogenesis ; serum biomarker ; IP-10/CXCL10 ; early diagnosis ; Lung cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test